Epacadostat: tested with established drugs
34 studies: they are given beside it. Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian CancerCompletedNCT03602586Phase 2Results postedHow we knowReport a problem
- Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior ImmunotherapyTerminatedNCT03463161Phase 2Results postedHow we knowReport a problem
- A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingNCT03414229Phase 2Results postedHow we knowReport a problem
- Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial CarcinomaCompletedNCT03374488Phase 3Results postedHow we knowReport a problem
- Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)CompletedNCT03361865Phase 3Results postedHow we knowReport a problem
- A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)TerminatedNCT03347123Phase 1/2Results postedHow we knowReport a problem
- A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)CompletedNCT03322566Phase 2Results postedHow we knowReport a problem
- Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)CompletedNCT03322540Phase 2Results postedHow we knowReport a problem
- Epacadostat and Pembrolizumab in Patients With GISTTerminatedNCT03291054Phase 2Results postedHow we knowReport a problem
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)CompletedNCT03260894Phase 3Results postedHow we knowReport a problem
- Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric CancerCompletedNCT03196232Phase 2Results postedHow we knowReport a problem
- A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)CompletedNCT03085914Phase 1/2Results postedHow we knowReport a problem
- Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)CompletedNCT02862457Phase 1Results postedHow we knowReport a problem
- A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)CompletedNCT02752074Phase 3Results postedHow we knowReport a problem
- Pembrolizumab and Epacadostat in Patients With Thymic CarcinomaStatus unknownNCT02364076Phase 2Results postedHow we knowReport a problem
- A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)CompletedNCT02327078Phase 1/2Results postedHow we knowReport a problem
- A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)CompletedNCT02318277Phase 1/2Results postedHow we knowReport a problem
- Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersCompletedNCT02178722Phase 1/2Results postedHow we knowReport a problem
- Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV MelanomaCompletedNCT01961115Phase 2Results postedHow we knowReport a problem
- Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal CancerWithdrawnNCT04231864Phase 2How we knowReport a problem
- Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR StudyWithdrawnNCT03832673Phase 2How we knowReport a problem
- Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal CancerWithdrawnNCT03592407Phase 2How we knowReport a problem
- Epacadostat, Cladribine and Cytarabine (ECC) in AMLWithdrawnNCT03491579Phase 1How we knowReport a problem
- Epacadostat, Idarubicin and Cytarabine (EIC) in AMLWithdrawnNCT03444649Phase 1How we knowReport a problem
- Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic CancerWithdrawnNCT03432676Phase 2How we knowReport a problem
- ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung CancerWithdrawnNCT03402880Phase 2How we knowReport a problem
- Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT03325465Phase 2How we knowReport a problem
- A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial CarcinomaWithdrawnNCT03310567Phase 2How we knowReport a problem
- A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 TherapyWithdrawnNCT03238638Phase 2How we knowReport a problem
- Epacadostat (INCB24360) in Combination With Sirolimus in Advanced MalignancyActive, not recruitingNCT03217669Phase 1How we knowReport a problem
- Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal CancerWithdrawnNCT03182894Phase 1/2How we knowReport a problem
- A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaTerminatedNCT02298153Phase 1How we knowReport a problem
- Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerCompletedNCT02118285Phase 1How we knowReport a problem
- A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaTerminatedNCT01604889Phase 1/2How we knowReport a problem